Public Release: 

Genetic test may improve post-stent treatment, outcome

Circulation: Genomic and Precision Medicine Journal Report

American Heart Association

DALLAS, April 3, 2018 - Using genetic testing to inform which blood thinner to use following a procedure to open narrowed blood vessels resulted in significantly fewer complications among patients, according to new research in Circulation: Genomic and Precision Medicine, an American Heart Association journal.

In the United States, heart disease is the leading cause of death, and stroke is the fifth-leading cause. A major contributor to these cardiovascular diseases is clogged blood vessels (atherosclerosis), which result from the buildup of fatty deposits or plaque.

Treatment for clogged blood vessels often includes angioplasty. In this procedure, the doctor inserts a small, medical balloon into the damaged blood vessels, and then inflates and removes it. Small tubes, or stents, also may be used to hold open the blood vessels. To prevent further damage from occurring, patients often take multiple blood thinners, such as clopidogrel and aspirin, after stent placement.

Previous research has shown that clopidogrel is less effective in patients with mutations on a specific gene, called CYP2C19, than in patients without the mutations. Whether genetic testing can help guide treatment in clinical practice, however, has remained unclear.

In this study, results showed that genetic testing for CYP2C19 mutations could be used to guide blood-thinner treatment after stent placement. Furthermore, patients with the mutations who received one of two clopidogrel alternatives compared to clopidogrel were more than three times less likely to die or have a heart attack, stroke or other major complications 12 months after treatment. Specifically, major complications occurred among 27 percent of clopidogel patients with the genetic mutations, compared to 8 percent of patients with the mutations who received the alternative medications.

These findings are similar to those of an earlier, multicenter study that found the risk of a major cardiovascular event more than doubled in patients with the genetic mutations who took clopidogrel.

"Using an algorithm based on genetic testing to guide treatment is sustainable and associated with better clinical outcomes in a real-world clinical practice, although it is difficult to consistently maintain," said Craig R. Lee, Pharm.D., Ph.D., F.A.H.A., associate professor of pharmacy at the University of North Carolina at Chapel Hill Eshelman School of Pharmacy. "Clinicians need to be aware of the increased risk of major adverse cardiovascular events associated with use of clopidogrel in patients receiving stents who carry either one or two copies of the mutation."

Study participants included 1,193 patients at the University of North Carolina Cardiac Catheterization Laboratory who received stent placement between July 1, 2012, and June 30, 2014. Their average age was 63 years and more than two-thirds were male. Most were white, 21 percent were black, and 1 percent was Asian. Patients identified as high risk, due to decreased blood flow to the heart, received the genetic testing. Follow up was 12 months.

The study has several limitations. For one, the investigators collected information after treatment, so they could not definitively say whether blood-thinner choice and the results of genetic testing caused better patient outcomes. Another limitation includes the use of a single hospital, which may not be applicable to different settings.

"We are using CYP2C19 genetic testing on a daily basis at our institution to help decide in a timely manner which drug to prescribe," said George "Rick" Stouffer, III, M.D., F.A.H.A., chief of cardiology and co-director of the McAllister Heart Institute at UNC.

###

Co-authors are Vindhya B. Sriramoju, M.D.; Alexandra Cervantes, B.S.; Lucius A. Howell, M.D.; Nicholas Varunok, M.S.; Shivanshu Madan, M.D.; Kasey Hamrick, Pharm.D.; Melissa J. Polasek, Pharm.D.; John Andrew Lee, Pharm.D.; Megan Clarke, Pharm.D.; Jonathan D. Cicci, Pharm.D.; Karen E. Weck, M.D.; and George A. Stouffer, M.D. Author disclosures are on the manuscript.

Additional Resources:

Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association's policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations and health insurance providers are available at http://www.heart.org/corporatefunding.

About the American Heart Association

The American Heart Association is devoted to saving people from heart disease and stroke - the two leading causes of death in the world. We team with millions of volunteers to fund innovative research, fight for stronger public health policies and provide lifesaving tools and information to prevent and treat these diseases. The Dallas-based association is the nation's oldest and largest voluntary organization dedicated to fighting heart disease and stroke. To learn more or to get involved, call 1-800-AHA-USA1, visit heart.org or call any of our offices around the country. Follow us on Facebook and Twitter.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.